Results 141 to 150 of about 22,784 (283)

Plant Proteins as Emulsifiers in the Food Industry: Research Progress, Current Challenges and Future Trends

Journal of the American Oil Chemists' Society, Volume 103, Issue 2, Page 99-121, February 2026.
ABSTRACT The impressive growth in the global market for plant‐based foods has a direct impact on the food industry, requiring greater efforts in product reformulation for the replacement of animal‐based ingredients, including proteins. The replacement of animal‐derived proteins frequently applied as emulsifiers in food formulations, for example ...
Thais C. Brito‐Oliveira, Talita A. Comunian, Samantha C. Pinho   +2 more
wiley   +1 more source

In-Vitro Studies on Selected Jordanian Plants as Dipeptidyl Peptidase-IV Inhibitors for Management of Diabetes Mellitus. [PDF]

Iran J Pharm Res, 2020
Sewidan N, Abu Khalaf R, Mohammad H, Hammad W.   +3 more
europepmc   +1 more source

GLP‐1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study

BJUI Compass, Volume 7, Issue 2, February 2026.
Abstract Objectives The purpose of this study is to investigate the impact of Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) use on 90‐day postoperative outcomes and overall survival following partial nephrectomy (PN) for renal cell carcinoma (RCC), where type 2 diabetes mellitus (T2DM) is a common comorbidity.
Sam Kwon, Fiona Wardrop, Diego Gonzalez, Francis Ryan, Liza Khutsishvili, Rollins Turner, Mohammad Ghassab Deameh, Michael J. Whalen   +7 more
wiley   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 579-588, February 2026.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman, Victoria E. Parker, Carmel M. McEniery, Giovanni Di Stefano, Annette Hubsch, Evangelia Vamvaka, Jo Helmy, Fotini Kaloyirou, Navazh Jalaludeen, Peter Barker, Lutz Jermutus, Joseph Cheriyan, Philip Ambery, Ian B. Wilkinson   +13 more
wiley   +1 more source

Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554

, 2011
Hironobu Maezaki, Yoshihiro Banno, Yasufumi Miyamoto, Yuusuke Moritou, Tomoko Asakawa, Osamu Kataoka, Koji Takeuchi, Nobuhiro Suzuki, Koji Ikedo, Takuo Kosaka, Masako Sasaki, Shigetoshi Tsubotani, Akiyoshi Tani, Miyuki Funami, Yoshio Yamamoto, Michiko Tawada, Kathleen Aertgeerts, Jason K. Yano, Satoru Oi   +18 more
openalex   +1 more source

Associations of Albuminuria and Metabolic Syndrome Traits With Fracture Risk in Patients With Type 2 Diabetes: A Population‐Based Cohort Study

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT Background Type 2 diabetes is associated with an increased risk of fragility fractures. While obesity may protect against fractures, individuals with type 2 diabetes often exhibit other metabolic syndrome (MetS) traits and albuminuria. We evaluated their roles and synergistic implications on incident fractures, stratified by obesity status ...
Xi Xiong, David T. W. Lui, Chengsheng Ju, Xiaodong Liu, Li Wei, Manju Chandran, Carlos K. H. Wong   +6 more
wiley   +1 more source

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Vildagliptin (VDG) is a dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor used for type 2 diabetes (T2DM) treatment. Viewing to improve VDG treatment, a population pharmacokinetic (popPK) model was built to describe drug plasma, free liver and muscle concentrations determined by microdialysis in healthy and diabetic animals following 50 mg/kg i.v ...
Bruna Bernar Dias, Laura Ben Olivo, Bibiana Verlindo de Araújo   +2 more
wiley   +1 more source

Amyloid Beta Precursor Protein: Proper Credit for the Basic Biochemical Properties of the Most Studied Protein in the 21st Century [PDF]

, 2015
The amyloid precursor protein (APP) is mainly known for being the precursor of the ß-amyloid peptide, which accumulates in plaques found in the brain of Alzheimer's disease patients.
Franco Fernández, Rafael, Martínez-Pinilla, Eva, Moreno Guillén, Estefanía, Navarro Brugal, Gemma   +3 more
core  

Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome

, 2011
Manabu Okawada, Jens J. Holst, Daniel H. Teitelbaum   +2 more
openalex   +2 more sources

A comprehensive study of ground-roasted coffee beans from Coffea liberica as dipeptidyl peptidase IV inhibitors

European Pharmaceutical Journal
Type 2 diabetes mellitus (T2DM), a degenerative disease characterized by insulin resistance, has been reported as a serious healthcare problem, especially in low-to-middle-income countries.
Riswanto Florentinus Dika Octa, Adventra Nicolaus De Deo, Priyambodo Gregorius Seno, Kusraynaldi Titus Marcel, Br Sembiring Angel Yemima Srininta, Larasati Theresia Niken, Windarsih Anjar, Wira Waskitha Stephanus Satria, Gani Michael Raharja, Istyastono Enade Perdana   +9 more
doaj   +1 more source